Gilead's CEO says oncology and inflammation push has reached 'critical mass'
Gilead's CEO says the company's diversification into oncology and inflammation has reached a critical mass after a series of acquisitions.
Gilead Sciences has been on an acquisition spree, and CEO Daniel O'Day says the company has now reached "critical mass" in its push into oncology and inflammation. The comment follows a series of deals, including three biotech buyouts completed earlier this year.
O'Day made the remarks in an interview with Fierce, as reported by both Fierce Pharma and Fierce Biotech. The two outlets carry the same account, indicating a consistent message from the CEO about the company's strategic direction.
The expansion marks a shift for Gilead, historically known for its antiviral drugs. With the recent acquisitions, the company aims to build a broader portfolio in cancer and inflammatory diseases, which O'Day described as the next chapter for the firm.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.